Gosset Year Founded
2013
Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 1
Modalities
ACM Biolabs General Information
ACM Biolabs has completed Phase 1 trials for its SARS-CoV-2 vaccine ACM-001, demonstrating safety and immunogenicity. The platform has shown potential for mucosal immunity and systemic immunogenicity.
Contact Information
Drug Pipeline
ACM-001
Phase 1Key Partnerships
No partnerships listed
ACM Biolabs Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | Sep 19, 2022 | $6.8M | Completed | Phase 1 |
To view ACM Biolabs's complete valuation and funding history, request access »
ACM Biolabs Investors
Key investor representation includes Erich Erber and Sang Bin through Ritz Venture Capital[6].
Investor Type: Venture Capital
Holding: Minority